Patents Assigned to Emisphere Technologies, Inc.
  • Publication number: 20210070691
    Abstract: Disclosed are improved methods for the synthesis of N-(8-[2-hydroxybenzoyl]- amino) caprylic acid. Certain compounds have been found useful for preventing the formation of a colored impurity when included in an ester hydrolysis reaction. Conducting ester hydrolysis in anaerobic conditions has also been found to minimize the formation of the color impurity. Also disclosed are improved methods for synthesizing the sodium salt of N-(8-[2-hydroxybenzoyl]-amino) caprylic acid.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: Emisphere Technologies, Inc.
    Inventors: William Elliot Bay, Joseph Norman Bernadino, George Frederick Klein, Yi Ren, Pingsheng Zhang
  • Patent number: 10875826
    Abstract: Disclosed are improved methods for the synthesis of N-(8-[2-hydroxybenzoyl]-amino) caprylic acid. Certain compounds have been found useful for preventing the formation of a colored impurity when included in an ester hydrolysis reaction. Conducting ester hydrolysis in anaerobic conditions has also been found to minimize the formation of the color impurity. Also disclosed are improved methods for synthesizing the sodium salt of N-(8-[2-hydroxybenzoyl]-amino) caprylic acid.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: December 29, 2020
    Assignee: Emisphere Technologies, Inc.
    Inventors: William Elliot Bay, Joseph Norman Bernadino, George Frederick Klein, Yi Ren, Pingsheng Zhang
  • Patent number: 10744105
    Abstract: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 18, 2020
    Assignee: Emisphere Technologies, Inc.
    Inventors: Halina Levchik, Shingai Majuru, Brahma Singh, Jamila Harris
  • Patent number: 9750710
    Abstract: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Emisphere Technologies, Inc.
    Inventors: Halina Levchik, Shingai Majuru, Brahma Singh, Jamila Harris
  • Publication number: 20160375135
    Abstract: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 29, 2016
    Applicant: Emisphere Technologies, Inc.
    Inventors: David GSCHNEIDNER, Stephen V. PUSZTAY
  • Patent number: 9458089
    Abstract: The present invention relates to particular phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering biologically active agents to a target. These compounds are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 4, 2016
    Assignee: Emisphere Technologies, Inc.
    Inventors: Gabriela Mustata, Dahua Pan, David Gschneidner
  • Publication number: 20160074420
    Abstract: Methods of normalizing vitamin B12 levels in patients with low vitamin B12 and methods of normalizing intersubject variability in the treatment of such patients are described. Methods of reducing MMA and/or homocysteine levels, and pharmaceutical compositions useful to effect such changes are also described.
    Type: Application
    Filed: November 30, 2015
    Publication date: March 17, 2016
    Applicant: Emisphere Technologies, Inc.
    Inventor: Cristina CASTELLI
  • Publication number: 20150321993
    Abstract: The present invention relates to particular phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering biologically active agents to a target. These compounds are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 12, 2015
    Applicant: Emisphere Technologies, Inc.
    Inventors: Gabriela Mustata, Dahua Pan, David Gschneidner
  • Patent number: 8975227
    Abstract: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: March 10, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Nai Fang Wang, Puchun Liu, Steven Dinh, Michael M. Goldberg, Ehud Arbit
  • Patent number: 8962554
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 24, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Ehud Arbit, Michael Goldberg, Shingai Majuru
  • Patent number: 8952017
    Abstract: The present invention relates to an acyclovir formulation having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 10, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Amy C. Adams, Brahma N. Singh, Nikhil Dhoot, Shingai Majuru
  • Patent number: 8927015
    Abstract: Oral insulin formulations and processes for preparing oral insulin formulations are provided.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: January 6, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Halina Levchik, Moses O. Oyewumi, Shingai Majuru, William Elliott Bay, Jun Liao, Puchun Liu, Steven Dinh, Nikhil Dhoot
  • Patent number: 8895777
    Abstract: The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: November 25, 2014
    Assignee: Emisphere Technologies Inc
    Inventors: Jun Liao, Pingwah Tang, David Gschneidner, Jonathan Maeyer
  • Publication number: 20140206612
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Ehud ARBIT, Michael GOLDBERG, Shingai MAJURU
  • Patent number: 8785381
    Abstract: The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: July 22, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventor: Donald J. Sarubbi
  • Patent number: 8771712
    Abstract: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a acyclovir compound. Methods of treatment, and methods of preparing the topical composition are also provided.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: July 8, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Steven Dinh, Puchun Liu, Ihor Shevchuk
  • Publication number: 20140187813
    Abstract: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Halina LEVCHIK, Shingai Majuru, Brahma Singh, Jamila Harris
  • Patent number: 8765796
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: July 1, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert J. Herr, Louis N. Jungheim, John M. McGill, Kenneth J. Thrasher, Muralikrishna Valluri
  • Patent number: 8748383
    Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: June 10, 2014
    Assignees: Novartis AG, Emisphere Technologies, Inc.
    Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
  • Patent number: 8729016
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 20, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Ehud Arbit, Michael Goldberg, Shingai Majuru